Literature DB >> 17220238

Regional distribution of solute carrier mRNA expression along the human intestinal tract.

Yvonne Meier1, Jyrki J Eloranta, Jutta Darimont, Manfred G Ismair, Christian Hiller, Michael Fried, Gerd A Kullak-Ublick, Stephan R Vavricka.   

Abstract

Intestinal absorption of drugs, nutrients, and other compounds is mediated by uptake transporters expressed at the apical enterocyte membrane. These compounds are returned to the intestinal lumen or released into portal circulation by intestinal efflux transporters expressed at apical or basolateral membranes, respectively. One important transporter superfamily, multiple members of which are intestinally expressed, are the solute carriers (SLCs). SLC expression levels may determine the pharmacokinetics of drugs that are substrates of these transporters. In this study we characterize the distribution of 15 human SLC transporter mRNAs in histologically normal biopsies from five regions of the intestine of 10 patients. The mRNA expression levels of CNT1, CNT2, apical sodium-dependent bile acid transporter (ABST), serotonin transporter (SERT), PEPT1, and OCTN2 exhibit marked differences between different regions of the intestine: the first five are predominantly expressed in the small intestine, whereas OCTN2 exhibits strongest expression in the colon. Two transporter mRNAs studied (OCTN1, OATP2B1) are expressed at similar levels in all gut sections. In addition, ENT2 mRNA is present at low levels across the colon, but not in the small intestine. The other six SLC mRNAs studied are not expressed in the intestine. Quantitative knowledge of transporter expression levels in different regions of the human gastrointestinal tract could be useful for designing intestinal delivery strategies for orally administered drugs. Furthermore, changes in transporter expression that occur in pathological states, such as inflammatory bowel disease, can now be defined more precisely by comparison with the expression levels measured in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220238     DOI: 10.1124/dmd.106.013342

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  48 in total

1.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

Review 2.  Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.

Authors:  Stefan Oswald; Christian Gröer; Marek Drozdzik; Werner Siegmund
Journal:  AAPS J       Date:  2013-08-28       Impact factor: 4.009

3.  Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

Authors:  Taleah Farasyn; Alexandra Crowe; Oliver Hatley; Sibylle Neuhoff; Khondoker Alam; Jean Kanyo; TuKiet T Lam; Kai Ding; Wei Yue
Journal:  J Pharm Sci       Date:  2019-04-30       Impact factor: 3.534

4.  Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.

Authors:  Tycho Heimbach; Binfeng Xia; Tsu-han Lin; Handan He
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

5.  Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study.

Authors:  Tanja Dujic; Kaixin Zhou; Roger Tavendale; Colin N A Palmer; Ewan R Pearson
Journal:  Diabetes Care       Date:  2016-08-04       Impact factor: 19.112

Review 6.  Pharmacogenetics of the organic anion transporting polypeptide 1A2.

Authors:  Ryan M Franke; Lisa A Scherkenbach; Alex Sparreboom
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

7.  Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.

Authors:  Olena Kis; Jason A Zastre; Md Tozammel Hoque; Sharon L Walmsley; Reina Bendayan
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

8.  Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Authors:  Harunobu Tahara; Sook Wah Yee; Thomas J Urban; Stephanie Hesselson; Richard A Castro; Michiko Kawamoto; Doug Stryke; Susan J Johns; Thomas E Ferrin; Pui-Yan Kwok; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

Review 9.  Adenosine: an immune modulator of inflammatory bowel diseases.

Authors:  Jeff Huaqing Ye; Vazhaikkurichi M Rajendran
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 10.  Bile acid transporters.

Authors:  Paul A Dawson; Tian Lan; Anuradha Rao
Journal:  J Lipid Res       Date:  2009-06-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.